Drug intelligence / Profile preview

NDST2 small interfering RNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous
01

Overview

NDST2 small interfering RNA (siRNA) is a double-stranded RNA molecule designed to silence the expression of the N-deacetylase and N-sulfotransferase 2 (NDST2) gene through the RNA interference (RNAi) pathway. NDST2 is a Golgi-resident enzyme responsible for the N-deacetylation and N-sulfation of glucosamine residues during the biosynthesis of heparan sulfate proteoglycans (HSPGs). These HSPGs are critical components of the extracellular matrix and cell surface that modulate various signaling pathways involved in cell growth, migration, and tumor progression. In the context of hepatocellular carcinoma (HCC), NDST2 has been identified as a downstream target of the transcription factor FOXP4. Research indicates that NDST2 is upregulated in residual HCC cells following incomplete thermal ablation, contributing to malignant transformation and progression. Experimental use of NDST2 siRNA has demonstrated that knocking down this enzyme can inhibit the proliferation, migration, and invasion of liver cancer cells, suggesting that targeting the FOXP4/NDST2 axis may be a viable therapeutic strategy to prevent recurrence after ablation therapy.

Other names
NDST2 siRNANDST-2 siRNANDST 2 siRNAN-deacetylase and N-sulfotransferase 2 small interfering RNAsiRNA targeting NDST2
02

Targets

NDST2 (N-deacetylase and N-sulfotransferase 2)

Beyond the preview

Go deeper on NDST2 small interfering RNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NDST2 small interfering RNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call